Skip to main content
Premium Trial:

Request an Annual Quote

In Print: Pharmacogenomics Papers of Note


Expanding the Foundation for Personalized Medicine: Implications and Challenges for Dentistry.
Garcia I, Kuska R, Somerman MJ.
J Dent Res. 2013 May 20 [Epub ahead of print]

Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes.
McDonough CW, Gong Y, Padmanabhan S, et al.
Hypertension. 2013 May 20. [Epub ahead of print]

Pharmacogenomics and Cardiovascular Disease.
Weeke P, Roden DM.
Curr Cardiol Rep. 2013 Jul;15(7):376.

EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance.
Robinson KW, Sandler AB.
Curr Oncol Rep. 2013 May 16. [Epub ahead of print]

microRNA expression profile in stage III colorectal cancer: Circulating miR-18a and miR-29a as promising biomarkers.
Brunet A, Pericay C, Moya I, et al.
Oncol Rep. 2013 May 15. [Epub ahead of print]

Circulating melanoma cells as a predictive biomarker.
Karakousis G, Yang R, Xu X.
J Invest Dermatol. 2013 Jun;133(6):1460-2.

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.
Hertz DL, McLeod HL.
J Hum Genet. 2013 May 16. [Epub ahead of print]

Targeted therapy with kinase inhibitors in aggressive endocrine tumors.
Marotta V, Franzese MD, Del Prete M, et al.
Expert Opin Pharmacother. 2013 Jun;14(9):1187-203.

Warfarin pharmacogenomics in children.
Vear SI, Stein CM, Ho RH.
Pediatr Blood Cancer. 2013 May 16. [Epub ahead of print]

Personalized medicine in psychiatry: problems and promises.
Ozomaro U, Wahlestedt C, Nemeroff CB.
BMC Med. 2013 May 16;11(1):132. [Epub ahead of print]

A simple and reproducible breast cancer prognostic test.
Marchionni L, Afsari B, Geman D, Leek JT.
BMC Genomics. 2013 May 17;14(1):336. [Epub ahead of print]

Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.
Han X, Ji Y, Zhao J, Xu X, Lou W.
Tumour Biol. 2013 May 19. [Epub ahead of print]

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.
Johnson JA, Cavallari LH.
Pharmacol Rev. 2013 May 17;65(3):987-1009.

Identification and Analysis of in vivo VEGF downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies.
Brauer MJ, Zhuang G, Schmidt M, et al.
Clin Cancer Res. 2013 May 17. [Epub ahead of print]

Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.
Yee SW, Mefford JA, Singh N, et al.
J Hum Genet. 2013 May 16. [Epub ahead of print]